GABAergic drugs in the treatment of epilepsy: modern or outmoded?

Department of Clinical & Experimental Medicine, Division of Neurology, University Hospital Maggiore della Carità, Italy.
Future medicinal chemistry (Impact Factor: 3.31). 02/2011; 3(2):177-82. DOI: 10.4155/fmc.10.296
Source: PubMed

ABSTRACT Antiepileptic drugs have a number of mechanisms of action that target brain excitability systems. The potentiation of GABAergic inhibitory neurotransmission represents a classic and well-known antiseizure effect. Currently available GABAergic antiepileptic drugs mainly target GABA(A) receptor-associated complexes, GABA reuptake or GABA catabolism. All these compounds, although generally effective, are limited by their deleterious effects on cognition and behavior. The challenge will be to find GABAergic drugs that exhibit the beneficial effects, without the adverse ones.

  • [Show abstract] [Hide abstract]
    ABSTRACT: Antiepileptic drugs (AEDs) are currently used in both neurology and in psychiatry. It is generally accepted that GABA-ergic compounds have sedative and anxiolytic properties, whereas channel blockers are mood stabilizers. However, this paradigm is often challenged. This is related to the variety of mechanisms of action of individual AEDs on biological systems, only some of which are related to the desired CNS effect. At present, just a few AEDs are licensed for psychiatric indications, namely carbamazepine, valproate, lamotrigine and pregabalin. Data on other AEDs show potential benefits, but are still inconclusive in some cases. This article discusses molecular targets of AEDs relevant for their psychotropic properties with special attention to newest compounds. Current knowledge gaps are also highlighted.
    Expert Review of Neurotherapeutics 06/2013; 13(6):639-46. · 2.96 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The γ-aminobutyric acid (GABA) transporters (GATs) are key membrane transporter proteins involved in the termination of GABAergic signaling at synapses in the mammalian brain and proposed drug targets in neurological disorders such as epilepsy. To date, four different GAT subtypes have been identified: GAT1, GAT2, GAT3 and the betaine/GABA transporter 1 (BGT1). Owing to the lack of potent and subtype selective inhibitors of the non-GAT1 GABA transporters, the physiological role and therapeutic potential of these transporters remain to be fully understood. Based on bioisosteric replacement of the amino group in β-alanine or GABA, a series of compounds was generated, and their pharmacological activity assessed at human GAT subtypes. Using a cell-based [(3)H]GABA uptake assay, several selective inhibitors at human BGT1 were identified. The guanidine-containing compound 9 (2-amino-1,4,5,6-tetrahydropyrimidine-5-carboxylic acid hydrochloride) displayed more than 250 times greater potency than the parent compound β-alanine at BGT1 and is thus the most potent inhibitor reported to date for this subtype (IC50 value of 2.5 µM). In addition, compound 9 displayed about 400, 16 and 40 times lower inhibitory potency at GAT1, GAT2 and GAT3, respectively. Compound 9 was shown to be a substrate for BGT1 and to have an overall similar pharmacological profile at the mouse orthologue. Compound 9 constitutes an interesting pharmacological tool for specifically investigating the cellular pharmacology of BGT1 and is the first small-molecule substrate identified with such a high selectivity for BGT1 over the three other GAT subtypes.
    Neurochemical Research 05/2014; · 2.13 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors in the postsynaptic membrane are involved in fast excitatory signaling in the brain and their activation may lead to the firing of action potentials. Talampanel and perampanel were the first noncompetitive AMPA receptor antagonists to be tested as add-on drugs in patients with refractory partial seizures, and were found to be effective in improving seizure control. Due to an unfavorable kinetic and tolerability profile, talampanel clinical development in the field of epilepsy was discontinued early while perampanel has been recently approved in Europe and the USA as adjunctive therapy for adults with partial seizures with or without secondary generalization. The recommended perampanel starting dose is 2 mg/day once daily, which can be increased up to the recommended maintenance dose of 4-8 mg/day. Increments should be of 2 mg/day and based on clinical response and tolerability. Titration should be performed at 1-week intervals or at lower speed and a 12-mg daily dose should be considered after careful evaluation. To date, no serious and/or idiosyncratic adverse effects have been associated with this agent. Most frequently reported adverse effects are dizziness, ataxia, aggression, irritability, vertigo, somnolence, fatigue, headache and gait disturbance. Weight increase is the only non-neurological adverse effects associated with perampanel.
    Expert Review of Neurotherapeutics 06/2013; 13(6):647-55. · 2.96 Impact Factor